{"id":"CHEMBL100239","canonicalSmiles":"Nc1nc(N)c2c(Sc3ccccc3)cccc2n1","inchiKey":"BUFDQCGCADQQQY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TCMDC-131943","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TCMDC-131943"],"crossReferences":{"drugbank":["DB04163"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1013","canonicalSmiles":"N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1","inchiKey":"JAPHQRWPEGVNBT-UTUOFQBUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LORACARBEF","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lorabid"],"synonyms":["LY-163892","Loracarbef","Loracarbef hydrate"],"crossReferences":{"Wikipedia":["Loracarbef"],"drugbank":["DB00447"],"chEBI":["47544"]},"childChemblIds":["CHEMBL1200610"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1025","canonicalSmiles":"CC(C)OP(=O)(F)OC(C)C","inchiKey":"MUCZHBLJLSDCSD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOFLUROPHATE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Floropryl"],"synonyms":["Dyflos","Fluostigmine","Isoflurophate","NSC-727370"],"crossReferences":{"PubChem":["144206196","50113285"],"Wikipedia":["Diisopropyl_fluorophosphate"],"drugbank":["DB00677"],"chEBI":["17941"]},"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["EFO_0000516"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for glaucoma."}
{"id":"CHEMBL1097235","canonicalSmiles":"NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl","inchiKey":"HMEDEBAJARCKCT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZOSEMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azosemid","Azosemide","Diart","Luret"],"crossReferences":{"PubChem":["144206352","170465933"],"Wikipedia":["Azosemide"],"drugbank":["DB08961"],"chEBI":["31248"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL1098060","canonicalSmiles":"Cn1nc(C(=O)O)c2c1-c1nc(Nc3ccccc3)ncc1CC2","inchiKey":"ZOBRPBVIEUWYJR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1098060","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08355"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL115824","canonicalSmiles":"Nc1ccnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","inchiKey":"NVUDDRWKCUAERS-PNHWDRBUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Deaza-Adenosine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Deaza-Adenosine"],"crossReferences":{"PubChem":["26756663"],"drugbank":["DB04218"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1174","canonicalSmiles":"N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O","inchiKey":"CZKPOZZJODAYPZ-LROMGURASA-N","drugType":"Protein","blackBoxWarning":false,"name":"EPTIFIBATIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eptifibatide","Integrilin"],"synonyms":["Eptifibatide","Integrelin"],"crossReferences":{"DailyMed":["eptifibatide"],"PubChem":["144206056","170465043"],"Wikipedia":["Eptifibatide"],"chEBI":["291902"]},"childChemblIds":["CHEMBL4068311"],"linkedTargets":{"rows":["ENSG00000259207","ENSG00000005961"],"count":2},"linkedDiseases":{"rows":["HP_0002140","EFO_0006834","Orphanet_232","EFO_0001645","EFO_0000319","EFO_0004277","EFO_0003106","EFO_0008585","EFO_0000712","EFO_0008583","EFO_0000612","HP_0004419","EFO_0005672","EFO_0008586"],"count":14},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for recurrent thrombophlebitis and acute coronary syndrome and has 11 investigational indications."}
{"id":"CHEMBL1186579","canonicalSmiles":"C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5","inchiKey":"JVLBPIPGETUEET-GAAHOAFPSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYLNALTREXONE","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["MRZ-2663","Methylnaltrexone","Methylnaltrexone cation","Methylnaltrexone ion"],"crossReferences":{"DailyMed":["methylnaltrexone%20bromide"],"Wikipedia":["Methylnaltrexone"]},"childChemblIds":["CHEMBL470617","CHEMBL1201770"],"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0003086","MONDO_0004880","EFO_0010282","EFO_0008585","EFO_0001645","HP_0001410","MONDO_0004567","EFO_1000652","EFO_1000948","EFO_0005611","MONDO_0004565","HP_0002019"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and has 9 investigational indications."}
{"id":"CHEMBL118865","canonicalSmiles":"CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1","inchiKey":"NYKCGQQJNVPOLU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPIRADOLINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Spiradoline"],"childChemblIds":["CHEMBL2218921"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1200621","canonicalSmiles":"CO/N=C1\\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN.CS(=O)(=O)O","inchiKey":"JIYMVSQRGZEYAX-CWUUNJJBSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"GEMIFLOXACIN MESYLATE","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL430","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Factive","Gemifloxacin mesylate"],"synonyms":["Gemifloxacin mesilate","Gemifloxacin mesylate","Gemifloxacin methanesulfonate","LB 20304A","LB-20304A","SB-265805-S"],"crossReferences":{"DailyMed":["gemifloxacin%20mesylate"],"PubChem":["144205026","170465333","26749070"],"chEBI":["53749"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200763","canonicalSmiles":"O=C([O-])CNC(=O)c1ccccc1[131I].[Na+]","inchiKey":"XYITYKDGJLHYPW-UDYUCQKZSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"IODOHIPPURATE SODIUM I 131","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1681","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hippuran i 131","Hippuran-131","Hipputope","Iodohippurate sodium i 131"],"synonyms":["Iodohippurate i131 sodium","Iodohippurate sodium i 131","Iodohippurate sodium i-131","Iodohippurate sodium, i-131","Iodohippurate sodium,i-131","Sodium Iodohippurate (131I)","Sodium iodohippurate (131 i)","Sodium iodohippurate (131i)","Sodium iodohippurate (131i) injection","Sodium iodohippurate i 131"],"crossReferences":{"drugbank":["DB09382"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL1201251","canonicalSmiles":"Oc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1","inchiKey":"IIRWWTKISYTTBL-SFHVURJKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARBUTAMINE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Arbutamine"],"crossReferences":{"Wikipedia":["Arbutamine"],"drugbank":["DB01102"],"chEBI":["50580"]},"childChemblIds":["CHEMBL1200385"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for cardiovascular disease."}
{"id":"CHEMBL1201515","drugType":"Protein","blackBoxWarning":false,"name":"PEGVISOMANT","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Somavert"],"synonyms":["B-2036-PEG","B2036-PEG","Pegvisomant","Pegwisomant","Somavent","Trovert"],"crossReferences":{"DailyMed":["pegvisomant"],"DrugCentral":["5015"],"Wikipedia":["Pegvisomant"]},"linkedTargets":{"rows":["ENSG00000112964"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0009607","EFO_1001485","Orphanet_93276","MONDO_0021117","EFO_0000673","EFO_0004142","EFO_0001073","EFO_0000691"],"count":9},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for acromegaly and has 7 investigational indications."}
{"id":"CHEMBL1201735","canonicalSmiles":"Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1","inchiKey":"WSTCENNATOVXKQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BUPROPION HYDROBROMIDE","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL894","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aplenzin"],"synonyms":["BVF-033","Bupropion hbr","Bupropion hydrobromide"],"crossReferences":{"DailyMed":["bupropion%20hydrobromide"]},"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["MONDO_0002009","EFO_0003761","EFO_0003768"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for unipolar depression. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1215923","canonicalSmiles":"O=C(O)Cc1cccc(-c2cc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(-c4cccc(CC(=O)O)c4)c3)ccc2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c1","inchiKey":"RYWCQJDEHXJHRI-XJMXIVSISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIMOSIAMOSE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bimosiamose","TBC-1269"],"crossReferences":{"PubChem":["124894548","144206811"],"drugbank":["DB06197"]},"childChemblIds":["CHEMBL2146099"],"linkedTargets":{"rows":["ENSG00000188404","ENSG00000174175","ENSG00000007908"],"count":3},"linkedDiseases":{"rows":["EFO_0000676","EFO_0000341"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1229851","canonicalSmiles":"CC(C)CCC(=O)N1CCC[C@H]1C(=O)NCc1ccc(C(=N)N)cc1","inchiKey":"AEKJCSNKYXWOAQ-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1229851","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06936"]},"childChemblIds":["CHEMBL3423005"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1230062","canonicalSmiles":"O=C(O)COc1cc(Cl)ccc1C(=O)NCc1ccc(Br)cc1F","inchiKey":"ZLIGBZRXAQNUFO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230062","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07028"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1230245","canonicalSmiles":"C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(N)c2N1","inchiKey":"NDSDGUULXHNXGA-RPDRRWSUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RONOPTERIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-aminotetrahydrobiopterin","Ronopterin","VAS-203","VAS203","Vas203"],"crossReferences":{"drugbank":["DB12575"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1231124","canonicalSmiles":"Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1","inchiKey":"PDOQBOJDRPLBQU-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-1480","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-1480","AZD1480","Azd 1480","Azd-1480"],"crossReferences":{"drugbank":["DB12588"]},"linkedTargets":{"rows":["ENSG00000096968"],"count":1},"linkedDiseases":{"rows":["EFO_0002430","MONDO_0001056","EFO_0003060","EFO_0000311","EFO_0000479"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1233973","canonicalSmiles":"CCCCCCCCCCCC[N+](C)(C)[O-]","inchiKey":"SYELZBGXAIXKHU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Lauryldimethylamine N-Oxide","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lauryldimethylamine N-Oxide"],"crossReferences":{"PubChem":["26757705"],"drugbank":["DB04147"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235157","canonicalSmiles":"Oc1c(Br)c(Br)c(Br)c(Br)c1Br","inchiKey":"SVHOVVJFOWGYJO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTABROMOPHENOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207537","17389565","56436654"],"drugbank":["DB03167"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235660","canonicalSmiles":"O=C(Cc1cccs1)N1CCC(c2nc(-c3cccs3)no2)CC1","inchiKey":"SJEVDMFUHCVNPM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235660","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08471"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL125278","canonicalSmiles":"NC(=O)O","inchiKey":"KXDHJXZQYSOELW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBAMIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carbamic Acid"],"crossReferences":{"Wikipedia":["Carbamic_acid"],"drugbank":["DB04261"],"chEBI":["28616"]},"childChemblIds":["CHEMBL3560381"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1276010","canonicalSmiles":"C=CCCCCCCCCC(=O)O","inchiKey":"FRPZMMHWLSIFAZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UNDECYLENIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FEMA NO. 3247","NSC-2013","Undecylenate","Undecylenic Acid","Undecylenic acid"],"crossReferences":{"PubChem":["144205210","144210701","170465527","29215364","68715"],"drugbank":["DB11117"],"chEBI":["35045"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1278146","canonicalSmiles":"CCN(CC)CCN1CCc2[nH]c(/C=C3\\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O","inchiKey":"GKEYKDOLBLYGRB-LGMDPLHJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FAMITINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Famitinib","SHR-1020","SHR1020","Shr-1020"],"crossReferences":{"drugbank":["DB11741"]},"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000102755","ENSG00000037280","ENSG00000157404","ENSG00000113721","ENSG00000122025"],"count":7},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","EFO_0003869","EFO_0005922","EFO_0000365","MONDO_0024503","EFO_0000681","EFO_0000756","Orphanet_44890","MONDO_0007254","EFO_0001071","EFO_0004252","EFO_0003060","EFO_0000311","EFO_1001961","EFO_1001480","MONDO_0002974","EFO_0005537","MONDO_0008903"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications."}
{"id":"CHEMBL1387","canonicalSmiles":"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C","inchiKey":"ICTXHFFSOAJUMG-SLHNCBLASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NORETHYNODREL","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Enidrel","NSC-15432","Norethynodrel","Noretynodrel","SC-4642"],"crossReferences":{"PubChem":["11533052","144203910"],"Wikipedia":["Norethynodrel"],"drugbank":["DB09371"],"chEBI":["34895"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."}
{"id":"CHEMBL142438","canonicalSmiles":"N#N","inchiKey":"IJGRMHOSHXDMSA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITROGEN","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dinitrogen","E-941","E941","INS NO.941","INS-941","Molecular nitrogen","Nitrogen","Nitrogen (n2)","Nitrogen gas","Nitrogen, liquid"],"crossReferences":{"drugbank":["DB09152"],"chEBI":["17997"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 15 investigational indications."}
{"id":"CHEMBL1442934","canonicalSmiles":"CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO","inchiKey":"OTKJDMGTUTTYMP-ROUUACIJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAFINGOL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-714503","SPC-100270","Safingol","Safingol hydrochloride"],"crossReferences":{"PubChem":["144204778","170466518","26754970","26754971"],"drugbank":["DB11924"]},"childChemblIds":["CHEMBL2107808"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1488165","canonicalSmiles":"O=C1CC[C@@H](C(=O)N2CSC[C@H]2C(=O)O)N1","inchiKey":"UUTKICFRNVKFRG-WDSKDSINSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIDOTIMOD","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-759841","Pidotimod","Pilimod"],"crossReferences":{"PubChem":["144205418","26719899","49648325"],"Wikipedia":["Pidotimod"],"drugbank":["DB11364"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1531134","canonicalSmiles":"CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1","inchiKey":"DKMFBWQBDIGMHM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MELPERONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bunil","FG 5111","FG-5111","Flubuperone","Melperone","Metylperon"],"crossReferences":{"PubChem":["144206136","170466288","50112880"],"drugbank":["DB09224"]},"childChemblIds":["CHEMBL4551527"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1566956","canonicalSmiles":"COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC","inchiKey":"YSIITVVESCNIPR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TROXIPIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aplace","Troxipide"],"crossReferences":{"PubChem":["144206934","170465889","26719893"],"Wikipedia":["Troxipide"],"drugbank":["DB13419"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL166863","canonicalSmiles":"CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O","inchiKey":"IJWPAFMIFNSIGD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"POLMACOXIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CG-100649","CG100649","Polmacoxib"],"crossReferences":{"drugbank":["DB12399"]},"linkedTargets":{"rows":["ENSG00000133742","ENSG00000073756","ENSG00000104267"],"count":3},"linkedDiseases":{"rows":["EFO_1000786","EFO_0004616","MONDO_0005178","EFO_0005755"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1672054","canonicalSmiles":"CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1","inchiKey":"XGGTZCKQRWXCHW-WMTVXVAQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CASOPITANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Rezonic","Zunrisa"],"synonyms":["Casopitant","GW-679769","GW679769","Gw679769"],"crossReferences":{"drugbank":["DB06634"]},"childChemblIds":["CHEMBL3542382","CHEMBL2107320"],"linkedTargets":{"rows":["ENSG00000115353"],"count":1},"linkedDiseases":{"rows":["EFO_0006911","MONDO_0002009","HP_0002017","EFO_0004888","EFO_1000781","HP_0002013","EFO_0004698","HP_0002018","EFO_0008533"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL1712842","canonicalSmiles":"CC(=O)O.CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1","inchiKey":"COBIOCPXKOZHSU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEPAZINE ACETATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL395110","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":[],"synonyms":["Mepazine acetate","NND 1964","Pecazine acetate"],"crossReferences":{"PubChem":["49645132"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States."}
{"id":"CHEMBL1743089","drugType":"Antibody","blackBoxWarning":false,"name":"VESENCUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MNRP-1685A","MNRP1685A","RG-7347","Vesencumab"],"linkedTargets":{"rows":["ENSG00000099250"],"count":1},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1753","canonicalSmiles":"CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1","inchiKey":"KDLRVYVGXIQJDK-AWPVFWJPSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CLINDAMYCIN","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antirobe","Cleocin","Cleocin T","Sobelin"],"synonyms":["7(s)-chloro-7-deoxylincomycin","Chlorodeoxylincomycin","Chlorolincomycin","Clindamycin","U-21,251","U-21251"],"crossReferences":{"DailyMed":["clindamycin%20hydrochloride"]},"childChemblIds":["CHEMBL1200588"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL187105","canonicalSmiles":"Oc1ccc2cc(-c3noc4cc(O)ccc34)ccc2c1","inchiKey":"LCGSYJVWLGYWTD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL187105","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07236"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL200469","canonicalSmiles":"CC(=O)c1ccc(NC(=O)c2cn[nH]c2-c2cc(Cl)c(O)cc2O)cc1","inchiKey":"BTTFXKUTBNGQTP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL200469","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06956"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2051956","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1","inchiKey":"SVJMLYUFVDMUHP-MGBGTMOVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXNIGULDIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(r)-niguldipine","Dexniguldipine","niguldipine"],"crossReferences":{"drugbank":["DB14068"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103831","canonicalSmiles":"COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1","inchiKey":"AKFJWRDCWYYTIG-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAPROXCINOD","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AR-P900758XX","AZD-3582","AZD3582","HCT 3012","HCT-3012","Naproxcinod","Naproxen-n-butyl nitrate","Nitronaproxen"],"crossReferences":{"drugbank":["DB06682"],"chEBI":["76254"]},"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["EFO_1000786","EFO_0001421","MONDO_0005178","EFO_0005755","EFO_1002048"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2103882","canonicalSmiles":"O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12","inchiKey":"UCEQXRCJXIVODC-PMACEKPBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIVANTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARQ 197","ARQ-197","Arq-197","Tivantinib"],"crossReferences":{"drugbank":["DB12200"]},"linkedTargets":{"rows":["ENSG00000105976"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007576","EFO_0000305","EFO_0003060","EFO_0000311","MONDO_0002691","MONDO_0001056","EFO_1001480","EFO_0000640","EFO_0003860","EFO_0000770","EFO_0000182","EFO_0000702","EFO_0000673","EFO_0001378","EFO_0000514","EFO_0000181"],"count":17},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications."}
{"id":"CHEMBL2104164","canonicalSmiles":"NC(=O)CN1Cc2ccccc2OC1=O","inchiKey":"KYCBWEZLKCTALM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAROXAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Caroxazone","F.I. 6654","FI-6654"],"crossReferences":{"drugbank":["DB09254"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL210593","canonicalSmiles":"Cc1cc(S(=O)(=O)N2CCC[C@H]2C(=O)O)c(N)cc1Cl","inchiKey":"OWYKAFABUYXQLE-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL210593","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07273"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107254","canonicalSmiles":"O=C1CN2CCOC2(c2ccccc2Cl)c2cc(Cl)ccc2N1","inchiKey":"ZIXNZOBDFKSQTC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOXAZOLAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cloxazolam","Sepazon"],"crossReferences":{"PubChem":["170465787"],"drugbank":["DB01553"],"chEBI":["31426"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107339","canonicalSmiles":"CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\\C(=O)O","inchiKey":"RPUBHMMISKEXSR-MLCLTIQSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESMIRTAZAPINE MALEATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1366933","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Esmirtazapine maleate","Mirtazapine maleate, (s)-","ORG 50081","ORG-50081","Org-50081"],"linkedTargets":{"rows":["ENSG00000274286","ENSG00000184160","ENSG00000102468","ENSG00000196639","ENSG00000147246","ENSG00000150594"],"count":6},"linkedDiseases":{"rows":["EFO_0004698"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2107371","canonicalSmiles":"CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O","inchiKey":"GWVQGVCXFNYGFP-PFHKOEEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SELODENOSON","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DTI-0009","GR-56072","GR56072","RG-14202","Selodenoson"],"linkedTargets":{"rows":["ENSG00000163485"],"count":1},"linkedDiseases":{"rows":["EFO_0000275"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2107380","canonicalSmiles":"CCOCCO[C@@H]1CC[C@@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\\C)[C@@H](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC","inchiKey":"YYSFXUWWPNHNAZ-PKJQJFMNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UMIROLIMUS","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["40-o-(2-ethoxyethyl)rapamycin","42-o-(2-ethoxyethyl) rapamycin","Biolimus","Biolimus a9","Rapamycin, 42-o-(2-ethoxyethyl)-","TRM 986","TRM-986","Umirolimus"],"crossReferences":{"drugbank":["DB15527"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107611","canonicalSmiles":"[Na+].[Na+].[S-2]","inchiKey":"GRVFOGOEDUUMBP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM SULFIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-41874","Sodium sulfide nonahydrate"],"crossReferences":{"drugbank":["DB11159"],"chEBI":["76208"]},"childChemblIds":["CHEMBL3989793"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2107777","canonicalSmiles":"CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC","inchiKey":"CDSBFDCCJJDFCV-CKZSCMLPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SATAVAPTAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Aquilda"],"synonyms":["SR 121463","SR 121463A","SR 121463B","SR-121463","SR-121463A","SR-121463B","SR121463B","SR121463F","Satavaptan","Satavaptan monophosphate","Satavaptan phosphate","Sr121463"],"linkedTargets":{"rows":["ENSG00000126895"],"count":1},"linkedDiseases":{"rows":["EFO_0001422","HP_0002902","EFO_1000982","HP_0001541"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2107876","drugType":"Enzyme","blackBoxWarning":false,"name":"CONDOLIASE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Condoliase","Hernicore","SI-6603"],"description":"Enzyme drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108250","drugType":"Enzyme","blackBoxWarning":false,"name":"ANISTREPLASE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eminase"],"synonyms":["APSAC","Anistreplase","BRL 26921","BRL-26921"],"linkedTargets":{"rows":["ENSG00000122194"],"count":1},"linkedDiseases":{"rows":["HP_0004419"],"count":1},"description":"Enzyme drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."}
{"id":"CHEMBL2108403","drugType":"Antibody","blackBoxWarning":false,"name":"EPITUMOMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epitumomab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108894","drugType":"Unknown","blackBoxWarning":false,"name":"ALGINIC ACID","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acidum alginicum","Alginate","Alginic acid","E-400","INS NO.400","INS-400","Landalgine","Landalgine p","Medisorb a","Satialgine h","Satialgine h 8"],"crossReferences":{"DrugCentral":["4321"]},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109268","drugType":"Antibody","blackBoxWarning":false,"name":"NARATUXIMAB EMTANSINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DEBIO-1562","IMGN-529","IMGN529","Imgn529","K7153a-smcc-dm1","Naratuximab emtansine"],"linkedTargets":{"rows":["ENSG00000104894"],"count":1},"linkedDiseases":{"rows":["EFO_0000095"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109310","drugType":"Antibody","blackBoxWarning":false,"name":"8H9 131I","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["8H9","8h9 131i"],"linkedTargets":{"rows":["ENSG00000103855"],"count":1},"linkedDiseases":{"rows":["EFO_1000026","EFO_1001012","MONDO_0002087","EFO_0000621"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109315","drugType":"Antibody","blackBoxWarning":false,"name":"MEDI-7184","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-7184"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2110700","canonicalSmiles":"CC[N+](C)(CC)CCOC(=O)C(O)(c1cccs1)C1CCCC1","inchiKey":"NEMLPWNINZELKP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTHIENATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Penthienate","Penthienate cation","Penthienate ion"],"crossReferences":{"drugbank":["DB13695"]},"childChemblIds":["CHEMBL2105315"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL240963","canonicalSmiles":"O=C1C=C(O)C(=O)c2ccccc21","inchiKey":"CSFWPUWCSPOLJW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAWSONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Hydroxynaphthoquinone","Lawsone","NSC-8625"],"crossReferences":{"PubChem":["26749851","50107733"],"Wikipedia":["Lawsone"],"drugbank":["DB04744"],"chEBI":["44401"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2447938","canonicalSmiles":"O=[O+][O-]","inchiKey":"CBENFWSGALASAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OZONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ozone","Triatomic oxygen"],"crossReferences":{"drugbank":["DB12510"],"chEBI":["25812"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL252556","canonicalSmiles":"COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O","inchiKey":"JGPMMRGNQUBGND-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IDEBENONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Raxone"],"synonyms":["Hydroxydecyl ubiquinone","Idebenone","NSC-759228","Oristar hdu","Sovrima"],"crossReferences":{"PubChem":["144205417","170465611","174006221","26719872","29216196"],"Wikipedia":["Idebenone"],"chEBI":["31687"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder and has 7 investigational indications."}
{"id":"CHEMBL270271","canonicalSmiles":"CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1","inchiKey":"DWRKFAJEBUWTQM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETACONAZOLE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CGA-64251","Etaconazole","Sonax"],"crossReferences":{"PubChem":["144211885","29217946"],"chEBI":["4874"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL274654","canonicalSmiles":"Cc1[nH]c(/C=C2\\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O","inchiKey":"NHFDRBXTEDBWCZ-ZROIWOOFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORANTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-702827","Orantinib","SU-6668","Su-6668","TSU-68"],"crossReferences":{"PubChem":["527809"],"drugbank":["DB12072"]},"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000066468","ENSG00000068078","ENSG00000077782","ENSG00000160867","ENSG00000113721"],"count":7},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","MONDO_0001056","MONDO_0008903","EFO_0000182","MONDO_0007254","MONDO_0002367","EFO_0001378","MONDO_0008315","EFO_1001951"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL285802","canonicalSmiles":"CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21","inchiKey":"HDOZVRUNCMBHFH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZOTEPINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zoleptil 100","Zoleptil 25","Zoleptil 50"],"synonyms":["Nipolept","Setous","Zotepin","Zotepine"],"crossReferences":{"PubChem":["144206686","170465934"],"Wikipedia":["Zotepine"],"drugbank":["DB09225"],"chEBI":["32316"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis."}
{"id":"CHEMBL292707","canonicalSmiles":"CC(C)Cc1ccc(C(C)C(=O)NO)cc1","inchiKey":"BYPIURIATSUHDW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IBUPROXAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ibudros","Ibuproxam","NSC-305528"],"crossReferences":{"drugbank":["DB08955"],"chEBI":["76160"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL297273","canonicalSmiles":"Nc1nc(O)c2nn(-c3cccc(C(=O)NCc4ccccc4Sc4ccccc4CO)c3)nc2n1","inchiKey":"IXDQOBDHBWEZOH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL297273","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03231"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL299233","canonicalSmiles":"CNCCCC1(c2ccccc2)OC(C)(C)c2ccccc21","inchiKey":"LJBBMCNHIUJBDU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TALOPRAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Talopram"],"crossReferences":{"drugbank":["DB09190"]},"childChemblIds":["CHEMBL2105328"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3185022","drugType":"Small molecule","blackBoxWarning":false,"name":"CHROMIUM PICOLINATE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207772"],"chEBI":["50369"]},"childChemblIds":["CHEMBL4297201"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3187683","canonicalSmiles":"CCCCCC[C@@H](CCC)C(=O)O","inchiKey":"YCYMCMYLORLIJX-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARUNDIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Arundic acid","MK-0724","MK0724","ONO-2506PO","Ono-2506po"],"crossReferences":{"PubChem":["144206875"],"drugbank":["DB05343"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL321130","canonicalSmiles":"N[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)NCc1cccc(Cl)c1","inchiKey":"CJHLRGCXPGIPCB-MOPGFXCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL321130","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06919"]},"childChemblIds":["CHEMBL599035"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL340813","canonicalSmiles":"Oc1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1","inchiKey":"RFSDQDHHBKYQOD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NU-6086","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NU-6086"],"crossReferences":{"drugbank":["DB08233"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3427435","canonicalSmiles":"O=C(O)CC[C@H](NP(=O)(O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)c1ccc(F)cc1)C(=O)O)C(=O)O)C(=O)O","inchiKey":"IZLOSIXADNUSCM-ACRUOGEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CTT-1057","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CTT1057","Ctt-1057","Ctt1057"],"crossReferences":{"drugbank":["DB14965"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3544910","drugType":"Small molecule","blackBoxWarning":false,"name":"MOTEXAFIN GADOLINIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Xcytrin"],"synonyms":["API-GP3","FP-GP1","GD-TEXAPHYRIN","Gd texaphyrin","Gd-Tex","Motexafin gadolinium","Motexafin gadolinium anhydrous","Motexafin gadolinium hydrate","NSC-695238","PCI-0120","gadolinium texaphyrin"],"crossReferences":{"chEBI":["50161"]},"linkedTargets":{"rows":["ENSG00000171848","ENSG00000167325","ENSG00000198431","ENSG00000048392"],"count":4},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0021321","EFO_0000681","EFO_1001465","EFO_0005952","EFO_0000228","EFO_0003060","EFO_0000632","EFO_0009708","EFO_0003863","EFO_0000095","MONDO_0008903","MONDO_0005411","MONDO_0002367","MONDO_0003869","EFO_0001378","EFO_0003833","MONDO_0024880","EFO_0000519","EFO_1000158"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."}
{"id":"CHEMBL362148","canonicalSmiles":"NC1=NCCS1","inchiKey":"REGFWZVTTFGQOJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Thiazolidin-(2E)-Ylideneamine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Thiazolidin-(2E)-Ylideneamine"],"crossReferences":{"drugbank":["DB02335"],"chEBI":["40889"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL379000","canonicalSmiles":"COC(=O)C(Cc1ccccc1)(Cc1ccc(NS(=O)(=O)O)cc1)C(=O)OC","inchiKey":"SUACYXRSGYYBGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL379000","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06989"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3813873","canonicalSmiles":"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1","inchiKey":"JGWRKYUXBBNENE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PEXIDARTINIB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["CML-261","PLX-3397","PLX3397","Pexidartinib","Plx-3397"],"crossReferences":{"DailyMed":["pexidartinib%20hydrochloride"],"drugbank":["DB12978"]},"childChemblIds":["CHEMBL3989973"],"linkedTargets":{"rows":["ENSG00000157404","ENSG00000182578","ENSG00000122025"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000685","EFO_0000756","Orphanet_44890","MONDO_0007254","EFO_0000222","EFO_1001106","MONDO_0008315","MONDO_0002171","EFO_1000562","EFO_0003968","EFO_0005537","EFO_0001421","EFO_0000673","EFO_0000183","EFO_0000760","EFO_0000519","EFO_0002617"],"count":18},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for tenosynovial giant cell tumor and neoplasm and has 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3828074","canonicalSmiles":"CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1","inchiKey":"REQQVBGILUTQNN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZIRITAXESTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["G-451990","G451990","GLPG-1690","GLPG1690","Glpg1690","Ziritaxestat","Ziritaxestatn"],"crossReferences":{"drugbank":["DB15403"]},"linkedTargets":{"rows":["ENSG00000136960"],"count":1},"linkedDiseases":{"rows":["EFO_0000768","EFO_0000717"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL395110","canonicalSmiles":"CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1","inchiKey":"CBHCDHNUZWWAPP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEPAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":[],"synonyms":["III-2318","Lacumin","Mepasin","Mepazin","Mepazine base","Meprazine","Mesapin","Nothiazine","P-391","Pacatal","Pacatal base","Pacatol","Pakatal","Paxital","Pecatal","Pecazine"],"crossReferences":{"PubChem":["144205395","29216162"]},"childChemblIds":["CHEMBL1712842"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States."}
{"id":"CHEMBL3989496","canonicalSmiles":"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\\F)c(=O)n1.O","inchiKey":"XPYQFIISZQCINN-QVXDJYSKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEZACITABINE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2105467","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anhydrous","FMDC","MDL 101,731","Tezacitabine","Tezacitabine monohydrate"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3989794","canonicalSmiles":"CCOC(=O)[C@H](CCCc1ccccc1)C1(C(=O)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O)CCCC1","inchiKey":"FVWPYVZWVOLAOP-DQEYMECFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAGLUTRIL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Daglutril","SLV-306","SLV306"],"linkedTargets":{"rows":["ENSG00000196549","ENSG00000117298"],"count":2},"linkedDiseases":{"rows":["EFO_0000537"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3989819","canonicalSmiles":"CCCn1c(=O)c2nc([C@H]3C[C@H]4C[C@@H]3[C@@H]3O[C@H]43)[nH]c2n(CCC)c1=O","inchiKey":"OQCJPFYWFGUHIN-GJKBLCTNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAXIFYLLINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BG-9719","BG9719","CVT-124","Naxifylline"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3989983","drugType":"Antibody","blackBoxWarning":false,"name":"COFETUZUMAB PELIDOTIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cofetuzumab pelidotin","PF-06647020"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL404849","canonicalSmiles":"CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1","inchiKey":"BFCDFTHTSVTWOG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULOCTIDIL","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Spain"," Germany"," France"],"classes":["Hepatotoxicity"],"year":1985},"tradeNames":[],"synonyms":["Bemperil","CP-556S","Cerebro","Circleton","Dulasi","Duloctil","Euvasal","Fluversin","Fluvisco","Hemoantin","Iangene","Loctidon","Locton","MJF 12637","MJF-12637","Octamet","Polivasal","Sudil","Suloctidil","Sulocton","Sulodene"],"crossReferences":{"PubChem":["104171389","144204409","170466521","26748521"]},"linkedTargets":{"rows":["ENSG00000075461","ENSG00000157388","ENSG00000142408","ENSG00000165995","ENSG00000100346","ENSG00000157445","ENSG00000151067","ENSG00000166862","ENSG00000148408","ENSG00000198216","ENSG00000105605","ENSG00000167535","ENSG00000006116","ENSG00000007402","ENSG00000081248","ENSG00000102001","ENSG00000151062","ENSG00000141837","ENSG00000130433","ENSG00000108878","ENSG00000075429","ENSG00000006283","ENSG00000182389","ENSG00000196557","ENSG00000153956","ENSG00000067191"],"count":26},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for cardiovascular disease. It was withdrawn in Spain,  Germany and  France initially in 1985 due to Hepatotoxicity."}
{"id":"CHEMBL406393","canonicalSmiles":"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C","inchiKey":"KXGVEGMKQFWNSR-LLQZFEROSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEOXYCHOLIC ACID","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kybella"],"synonyms":["ATX-101","ATX-101 (DEOXYCHOLIC ACID)","DWJ-211","DWJ211","Deoxycholate","Deoxycholic acid","Desoxycholic acid","NSC-8797"],"crossReferences":{"DailyMed":["deoxycholic%20acid"],"PubChem":["47193711","74413"],"Wikipedia":["Deoxycholic_acid"],"drugbank":["DB03619"],"chEBI":["28834"]},"childChemblIds":["CHEMBL1365278","CHEMBL1884070"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 investigational indications."}
{"id":"CHEMBL407009","canonicalSmiles":"NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1","inchiKey":"ACFIXJIJDZMPPO-NNYOXOHSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL407009","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02338"],"chEBI":["16474"]},"childChemblIds":["CHEMBL1256015"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL426559","canonicalSmiles":"CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3","inchiKey":"NXFFJDQHYLNEJK-CYBMUJFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAROPIPRANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cordaptive","Laropiprant","MK-0524"],"crossReferences":{"Wikipedia":["Laropiprant"],"drugbank":["DB11629"]},"childChemblIds":["CHEMBL218415","CHEMBL375527"],"linkedTargets":{"rows":["ENSG00000168229"],"count":1},"linkedDiseases":{"rows":["EFO_1000760","HP_0003124","MONDO_0021187","EFO_0001645","Orphanet_79211","MONDO_0005148","EFO_0004911","EFO_0000660","Orphanet_309005","HP_0031284"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4297270","canonicalSmiles":"Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1","inchiKey":"GQBRZBHEPUQRPL-LJQANCHMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-986020","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AP-3152 FREE ACID","Bms-986020"],"crossReferences":{"drugbank":["DB14948"]},"linkedTargets":{"rows":["ENSG00000198121"],"count":1},"linkedDiseases":{"rows":["EFO_0000768","EFO_1001993"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297297","canonicalSmiles":"CCCCCCCOC(=O)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CN1","inchiKey":"SZWIAFVYPPMZML-YNEHKIRRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KP-1461","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Kp 1461","Kp-1461"],"crossReferences":{"drugbank":["DB05644"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297386","canonicalSmiles":"COCCOc1cc(Cn2c(C(=O)O)c(-c3ccc(C(C)(C)C)cc3)c3ccccc32)cc(OCCOC)c1","inchiKey":"OIDYMQICWGYEDR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-376501","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-376501A","GSK376501","GSK376501A","Gsk-376501","Gsk376501"],"crossReferences":{"drugbank":["DB12654"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297412","canonicalSmiles":"CC1(C)C(/C=C/C2=C(Oc3ccc(C[C@H](NC(=O)c4ccc(NCc5cnc6nc(N)[nH]c(=O)c6n5)cc4)C(=O)O)cc3)/C(=C/C=C3/N(CCCCS(=O)(=O)O)c4ccc(S(=O)(=O)O)cc4C3(C)C)CCC2)=[N+](CCCCS(=O)(=O)O)c2ccc(S(=O)(=O)[O-])cc21","inchiKey":"PDXNSXLPXJFETD-DYVQZXGMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAFOLACIANINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OTL 0038","OTL 38","OTL-0038","OTL-38","OTL0038","OTL38","Otl-38","Otl0038","Otl38","Pafolacianine"],"crossReferences":{"drugbank":["DB15413"]},"childChemblIds":["CHEMBL4594383"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297669","canonicalSmiles":"CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC","inchiKey":"TZCPCKNHXULUIY-RGULYWFUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHATIDYL SERINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphatidyl serine","Phosphatidylserine","Phosphotidylserine"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297738","drugType":"Protein","blackBoxWarning":false,"name":"DALAZATIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dalazatide","SHK-186"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298192","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"SUVODIRSEN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMTR0139","Suvodirsen","WLS-4176","WV-3473","WVE-210201","Wve-210201"],"linkedTargets":{"rows":["ENSG00000198947"],"count":1},"linkedDiseases":{"rows":["Orphanet_98896"],"count":1},"description":"Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298201","drugType":"Gene","blackBoxWarning":false,"name":"SIMOLADAGENE AUTOTEMCEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OTL-101","Simoladagene autotemcel"],"description":"Gene drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL446036","canonicalSmiles":"O=CCC=O","inchiKey":"WSMYVTOQOOLQHP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MALONALDEHYDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Malondialdehyde"],"crossReferences":{"drugbank":["DB03057"],"chEBI":["566274"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4535757","canonicalSmiles":"C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1","inchiKey":"NXQKSXLFSAEQCZ-SFHVURJKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOTORASIB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lumakras"],"synonyms":["AMG-510","AMG510","Kras g12c inhibitor 9","Kras mutant-targeting amg 510","Sotorasib"],"linkedTargets":{"rows":["ENSG00000133703"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","EFO_0000365","EFO_0000571","MONDO_0008903","EFO_0001421","EFO_0003060"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 3 investigational indications."}
{"id":"CHEMBL458767","canonicalSmiles":"CCOP(=O)(OCC)C(=Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OCC)OCC","inchiKey":"YQLJDECYQDRSBI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SR-12813","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SR-12813"],"crossReferences":{"PubChem":["29217646"],"drugbank":["DB04466"],"chEBI":["77317"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594301","canonicalSmiles":"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1","inchiKey":"QMTKNJZIWGTNTE-LMOVPXPDSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"REMIMAZOLAM BESYLATE","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4297526","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Byfavo"],"synonyms":["BIPRAZINE PF","CNS 7056 besylate","CNS 7056B","CNS-7056 BESYLATE","CNS-7056B","GW-502056X","GW502056X","ONO-2745BS","ONO-IN-251","RF-10007","RF10007","Remimazolam besilate","Remimazolam besylate","SP148.5"],"crossReferences":{"DailyMed":["remimazolam%20besylate"]},"linkedTargets":{"rows":["ENSG00000182256","ENSG00000022355","ENSG00000011677","ENSG00000113327","ENSG00000163285","ENSG00000151834","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4594596","drugType":"Unknown","blackBoxWarning":false,"name":"REGN-4659","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["REGN-4659","REGN4659","Regn-4659","Regn4659"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL47259","canonicalSmiles":"CCCCCl","inchiKey":"VFWCMGCRMGJXDK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTYL CHLORIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Butyl chloride"],"crossReferences":{"PubChem":["144204623","144208063","17390003"],"Wikipedia":["1-Chlorobutane"],"drugbank":["DB11534"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL479527","canonicalSmiles":"CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC","inchiKey":"CMSGWTNRGKRWGS-NQIIRXRSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TORCETRAPIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CP-529,414","CP-529414","Torcetrapib"],"crossReferences":{"Wikipedia":["Torcetrapib"],"drugbank":["DB06281"],"chEBI":["49203"]},"linkedTargets":{"rows":["ENSG00000087237"],"count":1},"linkedDiseases":{"rows":["EFO_0004211","HP_0003124","MONDO_0021187","Orphanet_412","EFO_0001645","Orphanet_79211","EFO_0004911","Orphanet_413","Orphanet_309005"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL4802151","canonicalSmiles":"Cc1c(S(C)(=O)=O)c(-c2cc(F)cc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(C(=O)OCCCP(=O)(O)O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C","inchiKey":"QIOCQCYXBYUYLH-YACUFSJGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PELCITOCLAX","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pelcitoclax"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL486696","canonicalSmiles":"CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1.[Br-]","inchiKey":"OJIYIVCMRYCWSE-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"DOMIPHEN BROMIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1187011","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Domiphen bromide","NSC-39415","Oradol","Phenododecinium bromide"],"crossReferences":{"PubChem":["144204605","144207417","170465494","17389022"],"Wikipedia":["Domiphen_bromide"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL494089","canonicalSmiles":"CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21","inchiKey":"KGPGFQWBCSZGEL-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-690693","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK 690693","GSK690693","Gsk-690693"],"crossReferences":{"drugbank":["DB12745"],"chEBI":["90677"]},"linkedTargets":{"rows":["ENSG00000154229","ENSG00000142875","ENSG00000165059","ENSG00000065675","ENSG00000126583","ENSG00000171132","ENSG00000166501","ENSG00000105221","ENSG00000163558","ENSG00000117020","ENSG00000115825","ENSG00000067606","ENSG00000163932","ENSG00000027075","ENSG00000072062","ENSG00000142208","ENSG00000184304"],"count":17},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL497","canonicalSmiles":"Oc1c(I)cc(Cl)c2cccnc12","inchiKey":"QCDFBFJGMNKBDO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLIOQUINOL","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"," Germany"," France"," Japan"],"classes":["Neurotoxicity"],"year":1973},"tradeNames":["Domeform-hc","Oralcer","Quin-o-creme","Vioform"],"synonyms":["4-stearylamino-phenyl-trimethylam. metilsulf.","Clioquinol","Iodochlorhydroxyquin","Iodochlorhydroxyquinolone","NSC-3531","NSC-74938"],"crossReferences":{"PubChem":["104171297","11112285","124882179","124882180","144203967","144207489","170465019","17389542","24715134","26746922","85148761","855601"],"Wikipedia":["Clioquinol"],"drugbank":["DB04815"],"chEBI":["74460"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 investigational indications. It was withdrawn in United Kingdom,  United States,  Germany,  France and  Japan initially in 1973 due to Neurotoxicity."}
{"id":"CHEMBL52564","canonicalSmiles":"O=C(O)/C=C/c1ccccc1O","inchiKey":"PMOWTIHVNWZYFI-AATRIKPKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"O-COUMARIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(E)-2-Hydroxycinnamic Acid","(E)-Coumarinic Acid","2-Hydroxycinnamic Acid","3-(2-Hydroxyphenyl)Acrylic Acid","O-Coumaric Acid"],"crossReferences":{"drugbank":["DB01650"],"chEBI":["18125"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL53292","canonicalSmiles":"Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1","inchiKey":"YYUAYBYLJSNDCX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOXICAM","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Spain"," Germany"," France"],"classes":["Dermatological toxicity"],"year":1983},"tradeNames":["Maxicam"],"synonyms":["Isoxicam","NSC-758436","W 8495","W-8495"],"crossReferences":{"PubChem":["11112741","144204185","170466334","26747065","855966"],"drugbank":["DB08942"],"chEBI":["76163"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in Spain,  Germany and  France initially in 1983 due to Dermatological toxicity."}
{"id":"CHEMBL575","canonicalSmiles":"COc1cccc(OC)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12","inchiKey":"RJQXTJLFIWVMTO-TYNCELHUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHICILLIN","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["2,6-dimethoxyphenyl penicillin","Methicillin","Meticillin","Staphcillin"],"crossReferences":{"Wikipedia":["Meticillin"],"drugbank":["DB01603"],"chEBI":["6827"]},"childChemblIds":["CHEMBL1164","CHEMBL3181832"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL618","canonicalSmiles":"O=C(O)c1ccc(Cl)cc1","inchiKey":"XRHGYUZYPHTUJZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-CHLORO-BENZOIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Chlorobenzoic Acid"],"crossReferences":{"PubChem":["144214023","17388796","56436653"],"drugbank":["DB03728"],"chEBI":["30747"]},"childChemblIds":["CHEMBL1762652"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL632","canonicalSmiles":"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO","inchiKey":"UREBDLICKHMUKA-DVTGEIKXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BETAMETHASONE","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alphatrex","Betasolan","Betatrex","Betnelan","Celestone","Dermabet","Uticort"],"synonyms":["BETA-VAL","Betamethasone","Betatrex","Dermabet","Flubenisolone","Lotrisone","NSC-39470","SCH 4831","SCH-4831","Taclonex","Uticort","VISUBETA"],"crossReferences":{"PubChem":["144205668","144211772","170465027","26757820","46500420","56320847"],"Wikipedia":["Betamethasone"],"drugbank":["DB00443"],"chEBI":["3077"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["MONDO_0003005","EFO_0010822","EFO_1001034","EFO_1001494","EFO_1001104","HP_0012735","EFO_0000756","EFO_1001435","MONDO_0002959","EFO_1000644","MONDO_0005271","EFO_0000274","EFO_1000637","HP_0011868","HP_0004798","EFO_0009840","HP_0011950","EFO_0002950","MONDO_0005277","EFO_0000676","EFO_0004143","EFO_0009552","EFO_0003917","EFO_0009321","EFO_0008517","EFO_0005752","EFO_0005854","EFO_0009686","EFO_0000685","EFO_0008521","HP_0012532","EFO_1000906","HP_0000964","EFO_1001466","EFO_0000232","EFO_1001157","HP_0001742","HP_0006536","EFO_0004192","HP_0030833","EFO_0004209","EFO_0000516","MONDO_0002258","MONDO_0005178","EFO_1001434"],"count":45},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 25 investigational indications."}
{"id":"CHEMBL63560","canonicalSmiles":"C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1","inchiKey":"LKJPYSCBVHEWIU-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-BICALUTAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ICI-176334"],"crossReferences":{"PubChem":["144206041","144213865"],"Wikipedia":["Bicalutamide"],"drugbank":["DB02932"],"chEBI":["3090"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL65","canonicalSmiles":"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1","inchiKey":"VSJKWCGYPAHWDS-FQEVSTJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAMPTOTHECIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Camptothecin","Camptothecine","NSC-94600","Topotecan related compound c"],"crossReferences":{"PubChem":["11111011","11112910","11113913","124882713","124882714","26732559","26747153","26747154","26747155","399733","50104726","50104727","50123248","85231337","90340668"],"Wikipedia":["Camptothecin"],"drugbank":["DB04690"],"chEBI":["27656"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL69863","canonicalSmiles":"Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1","inchiKey":"CDRPUGZCRXZLFL-OWOJBTEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PICEATANNOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-365798"],"crossReferences":{"PubChem":["26753619","26753620","29215167","466622","50106772","50106773","50106774","56463614","90341169"],"drugbank":["DB08399"],"chEBI":["28814"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL8600","canonicalSmiles":"COc1cc(CC(C)N)c(OC)cc1C","inchiKey":"NTJQREUGJKIARY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-(2,5-Dimethoxy-4-Methyl-Phenyl)-1-Methyl-Ethylamine"],"crossReferences":{"drugbank":["DB01528"]},"childChemblIds":["CHEMBL558376","CHEMBL3247443"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
